Navigation Links
A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
Date:6/11/2008

Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a

New Report from Decision Resources

WALTHAM, Mass., June 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that induces closure and healing of fistulas in a greater percentage of patients than Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab) does, would earn a 30 percent patient share in the treatment of Crohn's disease, according to surveyed gastroenterologists.

The new report entitled Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab finds that surveyed gastroenterologists indicated that they would prescribe Centocor/Janssen-Cilag's ustekinumab to 30 percent of their patients with Crohn's disease. As a result, ustekinumab is forecasted to earn a 5.4 percent patient share of the U.S. Crohn's disease market in 2012.

The report also finds that UCB's Cimzia will earn Decision Resources' proprietary clinical gold standard ("clinical gold standard") status for the treatment of Crohn's disease by 2011 as interviewed gastroenterologists indicate that Cimzia's efficacy and delivery profiles are superior to those of the current clinical gold standard, Abbott/Eisai's Humira. Although surveyed gastroenterologists indicated that Cimzia has advantages in efficacy and delivery, the therapy may be associated with more minor side effects when compared to Humira.

"Interviewed gastroenterologists report that Cimzia's pegylated formulation may prolong the drug's effect, resulting in a slightly more effective maintenance therapy with a superior maintenance dosing schedule in comparison to Humira," said Kathryn Benton, analyst at Decision Resources. "As a result, we forecast Cimzia to replace Humira as the clinical gold standard because of its incremental advantage in delivery
'/>"/>

SOURCE Decision Resources Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
3. Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
4. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
5. Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile
10. A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimers Disease Drug Market
11. What are simple ways to judge the efficacy of 5-fluorouracil in colonic neoplasm?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 2015 , ... Dental practice in Los Angeles , Sunset Plaza Dental, ... that general health emergencies, such as broken arms or a heart attack, should be ... turn to during a dental emergency. This is important, because dental trauma is extremely ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results of a comprehensive survey ... Research and Policy Analysis show widespread support for the U.S. Affordable Care Act ... strongly agreed that the controversial law passed in 2010 had “more good than ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... development of it’s new program “Designing Secure Healthcare Systems” This three-day, highly ... technology leaders from healthcare organizations with access to the tactics, techniques and practices ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... study by the University of the Basque Country (UPV/EHU) ... emotional differences between the sexes and generations in terms ... than children, while women are better at forgiving than ... values, because it shows us what reasons people have ...
... CKD have an increased risk of adverse outcomes. Despite ... overt nephropathy develop End-Stage Renal Disease (ESRD) and/or succumb ... and ESRD may confound the estimates of risk for ... University of Helsinki, University Hospital of Helsinki and Folkhlsan ...
... By Alan Mozes HealthDay Reporter , ... bike-only tracks that are physically separated from street traffic ... vehicles, a new study finds. "We found that ... bicycling on cycle tracks, compared with bicycling in parallel ...
... Most people know that exercise is important ... and obesity rates are at all-time highs and ... study, University of Missouri researchers found that healthy ... significantly increased their physical activity levels. Conversely, interventions ...
... This release is available in French . ... speech experts will take centre stage in discussions on the ... of the American Association for the Advancement of Science in ... has been a driving force in revealing the unique window ...
... Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality ... radiation therapy in treating bone metastases. The guideline will ... OncologyBiologyPhysics , an official journal of ASTRO. Bone metastases ... bone. They can lead to debilitating effects including pain, ...
Cached Medicine News:Health News:Women are better at forgiving 2Health News:Competing risks analysis highlights new targets in preventing ESRD and death of diabetics 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 3Health News:To increase physical activity, focus on how, not why 2Health News:Canadian brainpower at AAAS in Washington 2Health News:ASTRO publishes palliative radiotherapy for bone metastases guideline 2
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... 11 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 6th Annual Healthcare Conference on Wednesday, November 18, at 8:30 ... may access a live webcast of the presentation on our ... It is recommended that listeners log on 15 minutes early ...
... NEW YORK, Nov. 11 Pulmo BioTech Inc. (OTC ... early experimental results have indicated that its PulmoBind(TM) product ... and follow-up of many conditions that affect the physical ... results, if confirmed by further experiments, would broaden the ...
Cached Medicine Technology:Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 2Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 3Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 4
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
Medicine Products: